A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
A study for patients with Metastatic Castration-resistant Prostate Cancer (mCRPC) using study drug JNJ-56021927
Sponsor: Johnson & Johnson
Enrolling: Male Patients Only
IRB Number: AAAP8905
U.S. Govt. ID: NCT02257736
Contact: Jivanny Rodriguez: 212-305-5098 / jr2850@columbia.edu
Additional Study Information: The purpose of this study is to compare the clinical benefit (i.e., does it help to improve or slow down the cancer) of adding study drug JNJ-56021927 to combined treatment of abiraterone acetate plus prednisone to treat patients with metastatic Castration-resistant Prostate Cancer (mCRPC). This study will also evaluate the possible side effects of study drug JNJ-56021927 and its effect on your body when given with abiraterone acetate and prednisone.
This study is closed
Investigator
Edward Gelmann, MD
Do You Qualify?
Do you have a confirmed diagnosis of prostate cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Jivanny Rodriguez
jr2850@columbia.edu
212-305-5098
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE